Profound Medical (TSE:PRN) has released an update.
Profound Medical has announced that its TULSA procedure will receive increased reimbursement under the new CMS rule, highlighting its advantage over other prostate treatment options. With a wider range of treatment settings and increased payment rates, TULSA is poised to redefine patient care with its incision-free approach.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
